Evaluation of Lipids, Drug Concentration, and Safety Parameters Following Cessation of Treatment With the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients With... by Gotto, Antonio M., MD, DPhil, Cannon, Christopher P., MD, Li, Xiujiang Susie, PhD, Vaidya, Sanskruti, MS, MPhil, Kher, Uma, MS, Brinton, Eliot A., MD, Davidson, Michael, MD, Moon, Jennifer E., PhD, Shah, Sukrut, PhD, RPh, Dansky, Hayes M., MD, Mitchel, Yale, MD, Barter, Philip, MD, PhD

Get full text

A Single-Dose Bioequivalence and Food Effect Study With Aprepitant and Fosaprepitant Dimeglumine in Healthy Young Adult Subjects by Shadle, Craig R., Murphy, M. Gail, Liu, Yang, Ho, Maureen, Tatosian, Daniel, Li, Susie (Xiujiang), Blum, Robert A.

Get full text

Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib by Lauring, Brett, Li, Xiujiang (Susie), Liu, Yang, Corr, Christy, Lazarus, Nicole, Cote, Josee, Larson, Patrick, Levonas, Amy O. Johnson, Lasseter, Kenneth C., Preston, Richard A., Smith, William B., Lai, Eseng, Wagner, John A.

Get full text

Single therapeutic and supratherapeutic doses of anacetrapib, a cholesteryl ester transfer protein inhibitor, do not prolong the QTcF interval in healthy volunteers by Lauring, Brett, Liu, Yang, Li, Xiujiang (Susie), Larson, Patrick, Moreau, Allison, Farmer, H. Frank, Johnson-Levonas, Amy O., Wagner, John A., Lai, Eseng

Get full text

Development of a Population Pharmacokinetic Model for Taranabant, a Cannibinoid-1 Receptor Inverse Agonist by Li, Xiujiang (Susie), Nielsen, Jace, Cirincione, Brenda, Li, Hankun, Addy, Carol, Wagner, John, Hartford, Alan, Erondu, Ngozi, Gantz, Ira, Morgan, Jerry, Stone, Julie

Get full text

Pharmacokinetics and Safety of Montelukast Oral Granules in Children 1 to 3 Months of Age With Bronchiolitis by Kearns, Gregory L., Lu, Susan, Maganti, Lata, Li, Xiujiang (Susie), Migoya, Elizabeth, Ahmed, Tuli, Knorr, Barbara, Reiss, Theodore F.

Get full text

Lipids, Safety Parameters, and Drug Concentrations After an Additional 2 Years of Treatment With Anacetrapib in the DEFINE Study by Gotto, Antonio M., Kher, Uma, Chatterjee, Manash Shankar, Liu, Yang, Li, Xiujiang Susie, Vaidya, Sanskruti, Cannon, Christopher P., Brinton, Eliot A., Moon, Jennifer E., Shah, Sukrut, Dansky, Hayes M., Mitchel, Yale, Barter, Philip

Request full text

EFFECTS OF LONGER-TERM TREATMENT WITH ANACETRAPIB ON SAFETY PARAMETERS, LIPIDS, AND PLASMA DRUG CONCENTRATIONS IN THE DEFINE TRIAL by Gotto, Antonio, Chatterjee, Manash Shankar, Liu, Yang, Li, Xiujiang Susie, Vaidya, Sanskruti, Kher, Uma, Cannon, Christopher, Brinton, Eliot, Davidson, Michael, Moon, Jennifer, Shah, Sukrut, Dansky, Hayes, Mitchel, Yale, Barter, Philip

Get full text

Lack of Effect of Aprepitant on Hydrodolasetron Pharmacokinetics in CYP2D6 Extensive and Poor Metabolizers by Li, Susie Xiujiang, Pequignot, Edward, Panebianco, Deborah, Lupinacci, Paul, Majumdar, Anup, Rosen, Laura, Ahmed, Tuli, Royalty, Jane E., Rushmore, Thomas H., Murphy, M. Gail, Petty, Kevin J.

Get full text

DEVELOPMENT OF A POPULATION PHARMACOKINETICS MODEL FOR TARANABANT: 152 by Nielsen, Jace, Cirincione, Brenda, Li, Xiujiang Susie, Li, Hankun, Addy, Carol, Wagner, John, Hartford, Alan, Erondu, Ngozi, Gantz, Ira, Morgan, Jerry D, Stone, Julie

Get full text